YCYoonyoung Choi

Yoonyoung Choi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yoonyoung Choi has a total of 68 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Reply to Hodges et al. Comment on “Kura et al. Cost-Effectiveness Analysis of Clesrovimab for Respiratory Syncytial Virus in Infants in the United States. Vaccines 2026, 14, 411”

    by Klodeta Kura, John C. Lang, Dawei Wang, Yoonyoung Choi, Michelle G. Goveia, Anushua Sinha, Yao-Hsuan Chen, Elamin H. Elbasha

    We thank the authors for their interest in our analysis

  • Open Access

    Cost-Effectiveness Analysis of Clesrovimab for Respiratory Syncytial Virus in Infants in the United States

    by Klodeta Kura, John C. Lang, Dawei Wang, Yoonyoung Choi, Michelle G. Goveia, Anushua Sinha, Yao-Hsuan Chen, Elamin H. Elbasha

    Background/Objectives: Respiratory syncytial virus (RSV) causes a significant hospitalization burden in infants. The objective of this study was to evaluate the cost-effectiveness of introducing clesrovimab, a recently approved long-acting monoclonal antibody, in all US infants born during or entering their first RSV season. Methods: A decision analytical model simulated the clinical and economic impact of clesrovimab in a yearly birth cohort, compared with three alternative interventions: nirsevimab, palivizumab, and the RSVpreF maternal vaccine. Model inputs were obtained from the published literature. Efficacy estimates for clesrovimab were derived from post hoc analyses of randomized control trial data, which were conducted to align endpoints from different studies (nirsevimab and RSVpreF). Medically attended lower respiratory infection (MALRI), quality-adjusted life years (QALYs, 3% discounting), and costs (in 2024 USD) were evaluated from a societal perspective. Both deterministic and probabilistic sensitivity analyses were performed. Results: Clesrovimab resulted in fewer (38,252) RSV-related MALRI outcomes and was cost-saving compared to nirsevimab, with significant reductions in total costs (USD 98 million saved). When compared with palivizumab, clesrovimab and nirsevimab were estimated to cost USD 38,655 and USD 79,912 per QALY, respectively. Results were sensitive to changes in intervention costs, efficacy, and QALY loss due to RSV infection. Conclusions: Clesrovimab may significantly reduce the burden of RSV among US infants in their first RSV season and may save costs compared to nirsevimab.


  • Open Access

    Assessment of physicians’ perception of pediatrics respiratory syncytial virus disease and preferences for immunization strategies in the United States

    by Yoonyoung Choi, Erwan Berjonneau, Bastien Vincent, Brian Dwyer, Bianca Chun, Tanaz Petigara, Xavier Guillaume

    Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infection in infants and young children, placing substantial burden on patients, their families, and health systems. This observational, cross-sectional, web-based, survey study in the United States (during October - November 2023) assessed physicians' perceptions of RSV disease and new immunization strategies, including their preferences for monoclonal antibodies (mAbs) and maternal immunizations as RSV preventive measures. Immunization preferences were quantified through discrete choice experiment (DCE). Physicians aged ≥ 18 years, who spent at least 60% of their time in direct patient care and worked in a practice providing immunization to patients aged ≤ 2 years were recruited through online panels. Eighty pediatricians and 20 family practitioners participated. Mean (SD) age of physicians was 52.3 (12.7) years; majority were male (64.0%). Most physicians strongly agreed with supporting all types of recommended childhood immunizations (77.0%) and were aware of new RSV immunization strategies under development or recently approved (91.0%). A majority moderately/strongly agreed that maternal immunization and mAbs provide protection to the baby (77.0% and 87.0%, respectively). In DCE, physicians chose RSV immunization 96.1% of the time vs no immunization (3.9%). The most important attributes that drove physicians' preferences were: increasing durability of protection from 90 to 180 days (24.9%), increasing efficacy against RSV hospitalization from 57% to 80% (20.9%), and increasing efficacy against medically-attended RSV from 51% to 80% (20.2%). Understanding physicians' attitudes and preferences regarding RSV immunization strategies is important as new RSV prevention methods become available and are introduced into clinical practice.


  • Open Access

    Readmission Following Respiratory Syncytial Virus Hospitalization among Children <5 Years of Age

    by Yoonyoung Choi, Evan Heller, Linda Amoafo, Yue Zhang, Kaleb Miller, Abbey Loveridge, Madelyn Ruggieri, Per Gesteland, Krow Ampofo

    Background: Hospitalization with lower respiratory infection (LRI) by Respiratory Syncytial Virus (RSV) and other respiratory viruses is common in young children. However, the likelihood of readmission following RSV LRI compared to other common respiratory viral infections is unknown. Methods: This prospective study included children <5 years and hospitalized with laboratory-confirmed RSV LRI at two hospitals in Salt Lake City, Utah, from October 31, 2019 to April 30, 2022. For comparison, we retrospectively identified children <5 years, hospitalized during the same period with Influenza virus (IV) or human metapneumovirus (hMPV) LRI. Readmissions were tracked for 1.5 years post-discharge. We calculated the incidence proportion of readmissions and estimated hazard ratios using Cox proportional hazards model with Covariate Balancing Propensity Score. Results: Among children hospitalized with RSV, IV, and hMPV LRI, all-cause hospital readmission was common, with 30-day readmission proportions ranging between 5% and 9% and increasing to between 19% and 30%, 1.5 years post-discharge. Respiratory-related readmission varied by virus, with RSV having higher proportions, increasing to 16.8% 1.5 years post-discharge, compared to 6%-7% with IV and hMPV. After adjusting for confounders, RSV hospitalization was associated with an increased hazard of respiratory-related readmission within 1.5 years after hospitalization compared to IV (HR 3.62, 95% CI, 1.13-11.64) or hMPV (HR 3.56, 95% CI, 1.14-11.06). Conclusion: Respiratory-related readmission proportion was higher and progressive over time among children <5 years with an index RSV admission compared to IV and hMPV. This underscores the critical need for prevention of RSV infection in infants and young children through RSV immunization strategies.


  • Open Access

    Respiratory Syncytial Virus Incidence in Young Children in the United States: Impact of Methodologies and Patient Characteristics

    by Sabina O. Nduaguba, Phuong T. Tran, Renata Shih, Lyn Finelli, Yoonyoung Choi, Yanning Wang, Almut G. Winterstein

    Objectives: This study aimed to estimate the incidence of respiratory syncytial virus (RSV) infections in US inpatient and outpatient settings.Methods: We established national cohorts of privately insured children < 5 years (2011–2019) to estimate annual and seasonal incidences of lower respiratory tract infection (LRTI), RSV‐LRTI, and RSV acute respiratory infection (RSV‐ARI), stratified by age and high‐risk conditions per American Academy of Pediatrics definitions. Sensitivity analyses varied episode definitions and assessed the impact of immunoprophylaxis and RSV under‐ascertainment.Results: Among 6,767,107 children, annual RSV‐LRTI rates dropped with increasing age in both inpatient (7.9 for age < 1 year to 0.2 for age 4 per 1000 person‐years) and outpatient settings (48.3 to 1.6). Most RSV‐ARI (~80%–90%) was RSV‐LRTI. RSV‐LRTI accounted for > half of LRTI hospitalizations among infants (7.9 RSV‐LRTI versus 14.7 LRTI) and for ~20% outpatient LRTI (48.3 versus 250.3), but this contribution declined with older age. Outpatient RSV‐LRTI was > 5 times inpatient rates.Inpatient RSV‐LRTI rates dropped consistently with increasing gestational age (GA) (35.6 for GA < 29 weeks versus 7.6 for term infants), while outpatient rates were similar across GA groups (54.0 versus 51.6). Infants with Down syndrome had the highest RSV‐LRTI rates, and any high‐risk group had rates >2 times higher than healthy term infants. Across all strata, seasonal rates were > 2 annual rates. Modeling suggested that claims data captured 42% of all RSV episodes.Conclusion: This study provides national, population‐based estimates of medically attended RSV infections across age groups and high‐risk strata. Results allow granular assessments of disease burden to guide recommendations for new RSV prevention strategies.


  • Open Access

    Economic Burden of Medically Attended Respiratory Syncytial Virus Infections Among Privately Insured Children Under 5 Years of Age in the USA

    by Phuong T. Tran, Sabina O. Nduaguba, Yanning Wang, Vakaramoko Diaby, Lynn Finelli, Yoonyoung Choi, Almut G. Winterstein

    Background: The cost of medically attended RSV LRI (lower respiratory infection) is critical in determining the economic value of new RSV immunoprophylaxes. However, most studies have focused on intermittent RSV encounters, not the episode of care that captures the entirety of RSV illness.Methods: We created age‐ and condition‐specific cohorts of children under 5 years of age using MarketScan® data (2015–2019). We contrasted aggregating healthcare costs over RSV‐LRTI episodes to ascertaining costs based on RSV‐specific encounters only. Economic burden was estimated by multiplying costs per encounter or per episode by their respective incidence rates.Results: Average cost was higher per episode than per encounter regardless of settings (inpatient: $28,586 vs. $18,056 and outpatient/ED: $2099 vs. $407 for infants). Across ages, the economic burden was highest for infants and RSV‐LRTI requiring inpatient care, but the burden in outpatient/ED settings was disproportionately higher than costs due to higher incidence rates (for inpatient vs. outpatient episodes: $226,403 vs. $101,269; for inpatient vs. outpatient encounters: $151,878 vs. $38,819 per 1000 infant‐years). For high‐risk children, cost and burden were up to 3–10 times higher, respectively.Conclusions: With a comprehensive stratification by settings and risk condition, the encounter‐ versus episode‐based estimates provide a robust range for policymakers' economic appraisal of new RSV immunoprophylaxes.


  • Open Access

    Cost of Medically Attended RSV Among Medicaid Beneficiaries ≤2 Years of Age by Underlying Risk Condition

    by Yoonyoung Choi, Lynn Finelli

    We evaluated costs for respiratory syncytial virus (RSV) medical attention in children aged <24 months using MarketScan® Medicaid Multi-State claims database 2015–2019. Average cost was highest for RSV hospitalization with intensive care unit (ICU) admission ($23 514–24 835), followed by no ICU admission ($8039–8990), ED visits ($463–482), and outpatient visits ($145–151). Cost was higher for those with comorbidities.


  • Open Access

    1346. The Risk of Readmission after RSV Hospitalization Among Children Younger than 5 Years

    by Yoonyoung Choi, Evan G Heller, Per H Gesteland, Linda Amoafo, Yue Zhang, Lyn Finelli, Krow Ampofo

    Respiratory Syncytial Virus (RSV) is one of the most common causes of childhood lower respiratory tract infection (LRTI) leading to hospitalization worldwide. Readmissions following viral LRTI hospitalization are common, however rates, timing and causes of readmission following RSV LRTI hospitalization are understudied. We evaluated readmissions occurring during 1-year post-discharge of RSV hospitalization. We prospectively identified children < 5 years of age hospitalized with laboratory-confirmed RSV LRTI at Primary Children’s and Riverton hospitals in Salt Lake City, Utah during the 2019-2020 RSV season. An electronic alert system identified all-cause readmission between November 2019 and April 2021. Discharge diagnoses of readmissions were reviewed by two pediatricians. We calculated the incidence rate of all-cause and respiratory-related readmission. A total of 297 children had laboratory-confirmed RSV LRTI hospitalizations during the 2019-2020 RSV season, with 24% admitted to the intensive care unit (ICU) during index RSV hospitalization and 24% having a chronic medical condition. During the 1-year follow-up period, 59 readmissions occurred among 47 patients (Table 1). The incidence rate of all-cause and respiratory-related readmission was 19.9 (95%CI 15.5-24.9) and 13.1 (95%CI 9.5-17.5) per 100 patients, respectively. Median age of readmitted patients was 11 months (interquartile range 5.9-11 months). Median number of readmissions was 1 (range: 1-4), with initial readmissions occurring within 28 days (median) of index admission; most (74%) due to a respiratory-related illness. Second and 3rd admissions were less common and occurred at 67 (median) and 160 (median) days respectively. During all readmissions, 19% of children required ICU admission and 25% had chronic medical conditions. All cause and respiratory readmission after Initial hospitalization with RSV LRTI commonly occurred among children < 5 years. These data support the need for RSV vaccines and immunoprophylaxis to prevent RSV hospitalization. A further study with a control group is needed to determine the role of RSV in readmission. Yoonyoung Choi, PhD, MS, RPh, Merck (Employee) Lyn Finelli, DrPH, MS, Merck (Employee)


  • Open Access

    Cost determinants among adults hospitalized with respiratory syncytial virus in the United States, 2017–2019

    by Yoonyoung Choi, Alexandra Hill‐Ricciuti, Angela R. Branche, William D. Sieling, Lisa Saiman, Edward E. Walsh, Matthew Phillips, Ann R. Falsey, Lyn Finelli

    Background: Respiratory syncytial virus (RSV) infections are common in adults, but data describing the cost of RSV‐associated hospitalization are lacking due to inconsistency in diagnostic coding and incomplete case ascertainment. We evaluated costs of RSV‐associated hospitalization in adult patients with laboratory‐confirmed, community‐onset RSV.Methods: We included adults ≥ 18 years of age admitted to three hospital systems in New York during two RSV seasons who were RSV‐positive by polymerase chain reaction (PCR) and had more than or equal to two acute respiratory infection symptoms or exacerbation of underlying cardiopulmonary disease. We abstracted costs from hospital finance systems or converted hospital charges to cost using cost‐charge ratios. We converted cost into 2020 US dollars and extrapolated to the United States. We used a generalized linear model to determine predictors of hospitalization cost, stratified by admission to intensive care units (ICU).Results: Cost data were available for 79% (601/756) of eligible patients. The mean total cost of hospitalization was $8403 (CI95 $7240–$9741). The highest costs were those attributed to ICU services $7885 (CI95 $5877–$10,240), whereas the lowest were radiology $324 (CI95 $275–$376). Other than longer length of stay, predictors of higher cost included having chronic liver disease (odds ratio [OR] 1.38 [CI95 1.05–1.80]) for patients without ICU admission and antibiotic use (OR 1.49 [CI95 1.10–2.03]) for patients with ICU admission. The annual US cost was estimated to be $1.2 (CI95 0.9–1.4) billion.Conclusion: The economic burden of RSV hospitalization of adults ≥ 18 years of age in the United States is substantial. RSV vaccine programs may be useful in reducing this economic burden.


  • Utilization of chronic lung disease treatment before the respiratory syncytial virus season as palivizumab prophylaxis qualifier in the American Academy of Pediatrics Guidelines

    by Yoonyoung Choi, H. Cody Meissner, Christian Hampp, Haesuk Park, Almut G. Winterstein

    Guidelines from the American Academy of Pediatrics recommend palivizumab immunoprophylaxis for children with CLD in their second year of life if they continue to need treatment within 6 months before the RSV season. The utilization patterns of treatment (chronic corticosteroid therapy, diuretic therapy, or supplemental oxygen) are not well understood. We examined variations in CLD treatment for ten consecutive 20-day segments preceding RSV season onset. Among infants and children with CLD (n = 19,026), 35.2% received one or more medical treatments for CLD any time within 200 days before entering the second RSV season: 8.6%, 3.2%, and 29.7% received supplemental oxygen, diuretics, and corticosteroids, respectively. Utilization decreased as infants’ age increased with corticosteroids surpassing oxygen and diuretics. To avoid the capture of intermittent use of corticosteroids for acute infections, we found requiring a minimum of 45 days cumulative exposure was reasonable to determine chronic use. What is Known: • Guidelines from the American Academy of Pediatrics recommend palivizumab immunoprophylaxis for children with CLD in their second year of life if they continue to need treatment within 6 months before the RSV season. • The utilization patterns of treatment (chronic corticosteroid therapy, diuretic therapy, or supplemental oxygen) are not well understood. A definition of chronic corticosteroid therapy in this setting is not available. What is New: • Among infants and children with CLD of prematurity, 35.2% received one or more medical treatments for CLD any time within 200 days before entering the second RSV season: 8.6%, 3.2%, and 29.7% received oxygen, diuretics, and corticosteroids, respectively. Utilization decreased as infants’ age increased with corticosteroids surpassing oxygen and diuretics. • A minimum of 45 days cumulative corticosteroid use within the past 90 days would accurately capture chronic use to fulfill criteria for immunoprophylaxis while limiting the inclusion of intermittent use of corticosteroids for acute infections.